Projects

IrsiCaixa is involved in a hundred national and international research projects active each year, funded by both public and private entities.

Keywords

Research group

Researcher

From date

To date

CELLRE - TRIM5-based gene therapy approaches for inducible cellular resistance to HIV-1

Project status

Ongoing

Start/End

2018

/

2023

Principal investigator

Julia García Prado

Financing entity

Grifols
Risk of vertical transmission of SARS-CoV-2 in mothers with active infection during delivery: the CoMBaT study (Covid19 Mother to Baby Transmission Study)

Project status

Ongoing

Start/End

2020

/

2021

Principal investigator

Cecilia Cabrera Navarro

Strategic lines

Cancer

Emerging infectious diseases
Fostering prophylactic and therapeutic strategies to fight the SARS-CoV-2 pandemic

Project status

Ongoing

Start/End

2020

/

2022

Principal investigator

Bonaventura Clotet Sala

Julià Blanco Arbués

Jorge Carrillo Molina

Nuria Izquierdo Useros

External researchers

Joquim Segalés, Julia Vergara-Alert, Alfonso Valencia, Victor Guallard

Participating entities

Barcelona Supercomputing Center (BSC), Animal Health Research Center (IRTA-CReSA)

Financing entity

Grifols
European Network for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Project status

Ongoing

Start/End

2016

/

2019

Principal investigator

Julià Blanco Arbués

Participating entities

Riga Stradiņš University (Latvia); London School of Hygiene and Tropical Medicine (UK); Charité–Universitätsmedizin Berlin (Germany); Vall d'Hebron University Hospital Foundation Research Institute (Spain); Germans Trias i Pujol Institute for Health Science Research (IGTP) (Spain); Oslo University Hospital (Norway); Università Degli Studi di Pavia (Italy); Azienda Ospedaliera Mellino Mellini di Chiari (Italy); State Research Institute/Centre for Innovative Medicine (Lithuania)

Strategic lines

Immunopathology

Microbiome

Global infectious diseases

Financing entity

European Commission

The main objectives of this European network is to establish a common European research platform for myalgic encephalomyelitis and chronic fatigue syndrome (ME/CFS). The project includes standardization of biobank procedures in new and existing facilities, adaptation of bioinformatic repositories and biostatistical databases to ELIXIR and BBMRI infrastructure standards (Work Package 1) and the mapping of existing knowledge in an integrated medical model for ME/CFS (Work Package 2).
Clinical response prediction and improvement for intravesical BCG treatment of superficial bladder cancer. BCG-INMUNO-RESP

Project status

Ongoing

Start/End

2014

/

2017

Principal investigator

Cecilia Cabrera Navarro

Participating entities

IrsiCaixa AIDS Research Institute, Germans Trias i Pujol University Hospital, Fight AIDS Foundation

Financing entity

Filantropia

BCG intravesical instillations play a key role in treating superficial bladder cancer by reducing recurrence and limiting progression. Despite its proven effectiveness, however, a significant proportion of patients are non-responders and so exposed to an increased risk of recurrence and progression. Unfortunately, no early response marker is available as yet in clinical practice. The objective is to identify factors that predict response to bladder treatment with BCG.
Glicoingeniería de nanovehículos para eliminar los reservorios virales; saf2017-91767-exp

Project status

Ongoing

Start/End

Principal investigator

Nuria Izquierdo Useros

Participating entities

Irsicaixa, ICN2, UPV-CSIC

Financing entity

MINECO
TISRESP - Tissue-resident memory cells as a potential immunotherapeutic target for combating mucosal infections

Project status

Ongoing

Start/End

2018

/

2023

Principal investigator

Cecilia Cabrera Navarro

Financing entity

Grifols
Glycoengineering nanovehicles to purge viral reservoirs

Project status

Ongoing

Start/End

2018

/

2021

Principal investigator

Nuria Izquierdo Useros

Participating entities

ICN2 and Biofisika-CISC

Financing entity

Spanish Ministry of Economy and Competitiveness, ref. SAF2017-91767-EXP.
HIV-specific immunity during treatment interruption (ATI) and its relationship to viral rebound and immune responses during acute HIV infection. New methos for ATI monituring in cure trials.

Project status

Ongoing

Start/End

2021

/

2023

Principal investigator

Beatriz Mothe Pujadas

Strategic lines

Immunopathology

Global infectious diseases

Therapies and vaccines

Financing entity

Ministerio de Ciencia, Innovación y Universidades - ISCIII

Fondo Europeo de Desarrollo Regional (FEDER)

Project Code PI20/01039

Team members: B. Mothe, A. Llano, S. Cedeño, M. Rosàs, T.Escribà, L. Bailón, Y. Alarcón.
Antiviral activity of Aplidin

Project status

Ongoing

Start/End

2020

/

2021

Principal investigator

Nuria Izquierdo Useros

Participating entities

IrsiCaixa, Animal Health Research Center (IRTA-CReSA)

Financing entity

Pharma Mar